- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Epitope mapping.
Displaying page 1 of 1.
EudraCT Number: 2021-001304-15 | Sponsor Protocol Number: AZGS2021005 | Start Date*: 2021-05-06 |
Sponsor Name:vzw az groeninge | ||
Full Title: COVID-19: Study of the immune response in healthy volunteers after vaccination against SARS-CoV-2 (COVID19-VAX-AZG) and monitoring of breakthrough infections after booster vaccination (COVID19-VAX-... | ||
Medical condition: immuneresponse after vaccination | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005450-30 | Sponsor Protocol Number: ABI-MS-P01 | Start Date*: 2014-01-08 |
Sponsor Name:Medizinische Universität Innsbruck | ||
Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment | ||
Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005197-19 | Sponsor Protocol Number: SIPPET2 | Start Date*: 2018-08-01 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: Inhibitor development in previously untreated patients with severe haemophilia A, first treated with plasma-derived factor VIII and then switched to recombinant product: an international, multicent... | |||||||||||||
Medical condition: Severe hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000988-68 | Sponsor Protocol Number: O2021-1 | Start Date*: 2021-03-31 |
Sponsor Name: Region Stockholm | ||
Full Title: Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 . | ||
Medical condition: Renal failure stage 4 and 5. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011186-88 | Sponsor Protocol Number: ABB-09-001 | Start Date*: 2009-09-08 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI | |||||||||||||
Full Title: Desarrollo de inhibidores en pacientes no tratados previamente (PUP) o en pacientes mínimamente tratados con componentes sanguíneos (MBCTP) al ser expuestos a concentrados de derivados plasmáticos ... | |||||||||||||
Medical condition: El estudio es un ensayo clínico abierto, aleatorizado, controlado, prospectivo, multicéntrico, internacional e independiente sobre la frecuencia de formación de inhibidores en pacientes no tratados... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Completed) PT (Completed) FR (Ongoing) DE (Completed) AT (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003427-38 | Sponsor Protocol Number: MOTIVATE | Start Date*: 2020-03-12 | |||||||||||
Sponsor Name:HZRM – Hämophilie-Zentrum Rhein Main GmbH | |||||||||||||
Full Title: MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial | |||||||||||||
Medical condition: Inhibitor-Positive patients with Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002554-23 | Sponsor Protocol Number: GENA-05 | Start Date*: 2013-02-19 | |||||||||||
Sponsor Name:OCTAPHARMA AG | |||||||||||||
Full Title: Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SI (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
